Immucor builds blood transfusion portfolio
This article was originally published in The Gray Sheet
Executive Summary
Immucor gains BioArray Solutions' BeadChip DNA analysis system for antigen determination for donors and recipients of blood transfusions under a $117 million acquisition deal announced March 11. The cash deal also gives Immucor a 19% equity interest in a new spin-off entity that will commercialize BioArray technology outside the fields of blood transfusion and transplantation. Immucor makes automated instruments and reagents that detect and identify the properties of cell and serum components of blood prior to transfusions
You may also be interested in...
Immucor Accepts $2 Billion Private Equity Buyout, But Open To Richer Offer
Blood transfusion testing product maker Immucor will gain added financial resources for future growth following investment firm TPG Capital’s purchase of the company for $1.97 billion, the firm announced July 5.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.